Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network. Leuk Lymphoma 2011 Sep;52(9):1675-80
Date
08/26/2011Pubmed ID
21864042Pubmed Central ID
PMC3489168DOI
10.3109/10428194.2011.580404Scopus ID
2-s2.0-80052062419 (requires institutional sign-in at Scopus site) 37 CitationsAbstract
Mantle cell lymphoma (MCL) is challenging to manage, with a median survival of 3-5 years. While intensive strategies are often appropriate for younger patients, these approaches are often not appropriate for older patients. In 2006, we reported our initial results using modified R-hyperCVAD (rituximab with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) with maintenance rituximab. The complete response rate was 64%, and median progression-free survival (PFS) 37 months. Herein, we update our results, now with a median follow-up of 62 months. The median PFS is unchanged and the median overall survival (OS) is 70 months. The proportion of patients surviving at 5 years is 62%, comparable to studies using intensive strategies in similar patient populations. No late toxicities were noted in our cohort. These long-term results suggest that the modified R-hyperCVAD regimen with maintenance rituximab is an excellent option for older patients with newly diagnosed mantle cell lymphoma.
Author List
Kenkre VP, Long WL, Eickhoff JC, Blank JH, McFarland TA, Bottner W, Rezazedeh H, Werndli JE, Bailey HH, Kahl BSAuthor
Jules H. Blank MD Adjunct Assistant Professor in the Medical School Regional Campuses department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAged
Aged, 80 and over
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents
Female
Follow-Up Studies
Humans
Induction Chemotherapy
Kaplan-Meier Estimate
Lymphoma, Mantle-Cell
Maintenance Chemotherapy
Male
Middle Aged
Neoplasm Staging
Pilot Projects
Remission Induction
Rituximab
Treatment Outcome
